Fludarabine Other names: Fludarabine phosphate Fludarabine (2F-ara-A)

Chemical formula: C₁₀H₁₃FN₅O₇P  Molecular mass: 285.235 g/mol  PubChem compound: 657237

Therapeutic indications

Fludarabine is indicated for:

B-cell chronic lymphocytic leukaemia (CLL)

Population group: only adults (18 years old or older)

Treatment of B-cell chronic lymphocytic leukaemia (CLL) in adult patients with sufficient bone marrow reserves.

First line treatment with Fludara should only be initiated in adult patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fludarabine is contraindicated in the following cases:

Lactation

Lactation

Severe renal impairment (creatinine clearance is <30 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Decompensated haemolytic anaemia

Hemolytic anemia

Renal impairment with creatinine clearance <30 ml/min

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: FLUDARA Powder for solution for injection or infusion
Summary of Product Characteristics (SPC) 2019: FLUDARA Film-coated tablets
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈